Experience

NH TherAguix

• France
• Research Services
• 1 - 100 Employee

• Chief Medical Officer

  • Sep 2022 - Present

  Paris, France Member of the executive committee NH TherAguix is a French clinical stage biotech specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy. NH TherAguix is a Phase II clinical stage developing AGuIX® radiosensitizing nanoparticles that increase the effectiveness of radiotherapy (RT). 60% of cancer patients will undergo a RT treatment. Designed to increase the dose differential between tumours and healthy tissues, AGuIX® also allows more accurate… Show more Member of the executive committee NH TherAguix is a French clinical stage biotech specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy. NH TherAguix is a Phase II clinical stage developing AGuIX® radiosensitizing nanoparticles that increase the effectiveness of radiotherapy (RT). 60% of cancer patients will undergo a RT treatment. Designed to increase the dose differential between tumours and healthy tissues, AGuIX® also allows more accurate RT imaging guidance. The combination of these three properties (targeting, imaging and treatment) paves the way for a new generation of precision radiotherapy. Show less



Onxeo S.A.

• France
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Chief Medical Officer

  • Feb 2017 - Sep 2022

  Région de Paris, France Member of Executive Committee -Active contribution to Company strategic development (Board of Directors, Comex), Investor’s meeting (ND Road shows in US & EU) and Business Development (Pharma/Biotech) -Head of Clinical Development , Regulatory Affairs, Pharmacovigilance and Quality Assurance -Managing Scientific Advices and Leading Relationships with Health Authorities -Developing KOLs, Scientific Advisory boards, Academics and Cooperative groups in Oncology AsiDNA® first… Show more Member of Executive Committee -Active contribution to Company strategic development (Board of Directors, Comex), Investor’s meeting (ND Road shows in US & EU) and Business Development (Pharma/Biotech) -Head of Clinical Development , Regulatory Affairs, Pharmacovigilance and Quality Assurance -Managing Scientific Advices and Leading Relationships with Health Authorities -Developing KOLs, Scientific Advisory boards, Academics and Cooperative groups in Oncology AsiDNA® first in class DNA damage repair inhibitor translation to FIM/early clinical development programs (MoA, biomarkers…) Show less



STALLERGENES GREER

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Vice President, Chief Medical Officer

  • 2005 - 2017

  Paris et périphérie - Member of Executive Committee - Active contribution in the Company Strategic Business Plan - Head of Global Clinical Development – Stalair® program at worldwide level - Head of Pharmacovigilance – Setting global PV system - Head of Global Medical Affairs and Outcome Research - Managing Scientific Advices and relationships with Health Authorities (US, EMA, PMDA, CFDA...) - Developing international relationships with KOLs and Decision Makers networking (HTAs) - Active… Show more - Member of Executive Committee - Active contribution in the Company Strategic Business Plan - Head of Global Clinical Development – Stalair® program at worldwide level - Head of Pharmacovigilance – Setting global PV system - Head of Global Medical Affairs and Outcome Research - Managing Scientific Advices and relationships with Health Authorities (US, EMA, PMDA, CFDA...) - Developing international relationships with KOLs and Decision Makers networking (HTAs) - Active collaboration with Scientific Societies in Allergic Respiratory Diseases (EAACI, AAAAI, WAO..) task forces, position papers, guidelines updates and scientific communications - Developing Affiliates’ Medical Affairs Network, Strategic plan implementation and compliance - Chairman of Committees (Publication, Corporate safety, Medical Affairs...) - Involved in external communication (financial analyst road shows, presentation to shareholders and journalists) Show less



IQVIA ( ex QUINTILES)

• Head of European Business Developement

  • 2002 - 2005

  - Reporting to the head of Quintiles Europe and member of the Executive Committee - Responsible for International Clinical Studies Business (Phase II to Phase IV studies). - Developing Strategic Relationships with pharmaceutical industries (Sanofi Aventis, Merck, AstraZeneca, Roche, Novartis, Janssen Cilag, Servier…) for Risk sharing programs. - Managing European team for successful bid defense meetings



Webhelp Medica

• France
• Business Consulting and Services
• 100 - 200 Employee

• Head of Business Development

  • 2000 - 2002

  Launching the Company and Developing Strategic Partnerships - Co-founding Direct Medica (Business Plan, Capital Venture and private investors). - Responsible for Business Development and commercial partnership with health care industries (Pharma, Cosmetics, Medical devices, Nutrition).



Sanofi (ex Aventis)

• Brand Manager for Doliprane

  • 1998 - 2000

  Marketing: Products Champion Doliprane® (Top 1 brand on the french market).

• Head of Medical Affairs for oncology, anti-infective, respiratory and gastrointestinal diseases.

  • 1996 - 1998

  - Coordinating Business Units Marketing Plans (P&L optimization). - Portfolio analysis (mix marketing & sales elasticity). - Managing outcome research studies (phases IV, observational & epidemiological studies). - Developing relationships with opinion leaders and health authorities.

• Corporate Marketing - Head of Global Medical Affairs for Oncology franchise

  • 1993 - 1996

  Taxotere, Campto and Granocyte